Analysts’ Weekly Ratings Changes for Xenon Pharmaceuticals (XENE)

A number of research firms have changed their ratings and price targets for Xenon Pharmaceuticals (NASDAQ: XENE):

• 5/2/2025 – Xenon Pharmaceuticals was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.
• 4/24/2025 – Xenon Pharmaceuticals was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
• 4/17/2025 – Xenon Pharmaceuticals had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $60.00 to $52.00. They now have a “buy” rating on the stock.
• 4/16/2025 – Xenon Pharmaceuticals was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.
• 4/6/2025 – Xenon Pharmaceuticals was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.
• 3/29/2025 – Xenon Pharmaceuticals was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.

Xenon Pharmaceuticals Stock Performance

Shares of XENE stock traded down $0.48 during mid-day trading on Monday, hitting $37.81. The company’s stock had a trading volume of 316,537 shares, compared to its average volume of 453,827. The stock has a market cap of $2.90 billion, a price-to-earnings ratio of -13.41 and a beta of 1.21. Xenon Pharmaceuticals Inc. has a 52-week low of $26.74 and a 52-week high of $46.00. The business has a 50-day moving average price of $34.74 and a 200 day moving average price of $38.53.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.84) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.05. Equities research analysts predict that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current fiscal year.

Institutional Investors Weigh In On Xenon Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in XENE. New York State Common Retirement Fund increased its position in Xenon Pharmaceuticals by 7.4% during the first quarter. New York State Common Retirement Fund now owns 142,372 shares of the biopharmaceutical company’s stock valued at $4,777,000 after acquiring an additional 9,851 shares during the last quarter. Mutual of America Capital Management LLC bought a new position in shares of Xenon Pharmaceuticals in the 1st quarter worth approximately $1,636,000. Bank of New York Mellon Corp boosted its holdings in shares of Xenon Pharmaceuticals by 439.0% in the first quarter. Bank of New York Mellon Corp now owns 251,147 shares of the biopharmaceutical company’s stock worth $8,426,000 after buying an additional 204,550 shares during the last quarter. GF Fund Management CO. LTD. grew its position in Xenon Pharmaceuticals by 21.9% during the first quarter. GF Fund Management CO. LTD. now owns 1,952 shares of the biopharmaceutical company’s stock valued at $65,000 after buying an additional 351 shares during the period. Finally, Assenagon Asset Management S.A. increased its holdings in Xenon Pharmaceuticals by 1.1% during the first quarter. Assenagon Asset Management S.A. now owns 241,206 shares of the biopharmaceutical company’s stock valued at $8,092,000 after buying an additional 2,684 shares during the last quarter. 95.45% of the stock is currently owned by hedge funds and other institutional investors.

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.